AbCellera
424 posts
AbCellera
@AbCelleraBio
AbCellera is clinical-stage biotech company focused developing antibody-based medicines in the areas of endocrinology, women’s health, immunology and oncology
Vancouver, British Columbia Katılım Ocak 2016
88 Takip Edilen7K Takipçiler
AbCellera to Present at Upcoming Investor Conferences in March and April 2026 investors.abcellera.com/news/news-rele…
English
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
investors.abcellera.com/news/news-rele…
English
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause investors.abcellera.com/news/news-rele…
English
AbCellera and Bruker Reach Global Settlement of Patent Litigation investors.abcellera.com/news/news-rele…
English
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 investors.abcellera.com/news/news-rele…
English
AbCellera Appoints Dr. Stephen Quake to its Board of Directors investors.abcellera.com/news/news-rele…
English
Visit our poster at ACoP 2025 Conference to learn how using Quantitative Systems Pharmacology (QSP) models can help predict and explain the diverse in vivo efficacy outcomes of T-cell engagers.
Read more about our TCE platform:tinyurl.com/a3csf7p3
#pharmacometrics #ISoP #ACoP
English
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
abcellera.com/news/abcellera…
English
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
abcellera.com/news/abcellera…
English
Visit our poster at #DiscoveryOnTarget in Boston to learn how our multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets.
Read more about our TCE platform:
tinyurl.com/yyv3nk54
English
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
abcellera.com/news/abcellera…
Français
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
ow.ly/XtfB50WBHnz
English
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
ow.ly/qXk350Wm1Bc
English
Visit our poster at Antibody Engineering & Therapeutics Europe 2025 to learn how we leverage multiple T-cell engager building blocks to generate molecules with in vivo efficacy.
Read more about our TCE platform: ow.ly/JzZt50W5EbV
#AntibodyEngineering
English
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
ow.ly/7GH550W1JLI
English